Review article

Novelties in immunotherapy of esophageal and stomach cancer

Vesna Bišof orcid.org/0000-0002-2826-9664 ; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia; Osijek University School of Medicine, Osijek, Croatia

Abstract

A high frequency of somatic mutations has been detected in stomach and esophageal cancers which makes them a possible suitable target for the application of immunotherapy. Contemporary immunotherapeutic approaches rely on monoclonal antibodies that inhibit immune checkpoints. The results of early clinical studies are promising, while only a few phase III studies have published their results so far. A particulary promising treatment strategy is the combination of checkpoint inhibitors with other treatment modalities, such as chemotherapy, targeted therapy, radiotherapy or T cells agonists.

Keywords

esophageal cancer; gastric cancer; checkpoint inhibitors; immunotherapy

Hrčak ID:

192191

URI

https://hrcak.srce.hr/192191

Publication date:

21.12.2017.

Article data in other languages: croatian

Visits: 1.264 *